Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiragolumab - Genetech

Next Previous
Drug Profile

Tiragolumab - Genetech

Alternative Names: MTIG-7192A; RG 6058; RO 7092284

Latest Information Update: 08 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Disulfides; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I B-cell lymphoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 05 Aug 2019 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT04045028)
  • 05 Aug 2019 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater, Monotherapy) in USA (IV) (NCT04045028)
  • 05 Aug 2019 Phase-I clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT04045028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top